از وب سايت جديد شركت به آدرس www.parsianazteb.ir دیدن فرمایید
در صورت مشاهده اختلال در خطوط ثابت شريت لطفا با شماره ۰۹۱۹۶۲۲۰۲۵۶تماس حاصل فرمایید
نمونه : خون کامل، سرم، پلاسما cut off : 0.5 ng/mL
تست تروپونین Getein Biotech Inc. یک تست سریع ایمونوکروماتوگرافیک جهت تشخیص تروپونین I قلبی در نمونه های پلاسما، سرم و خون کامل بیماران می باشد. این کیت جهت استفاده به عنوان روش کمکی در تشخیص سکته های قلبی ارائه شده است. این آزمایش در تشخیص به روش (in vitro) بیماری مذکور به کار برده می شود. نتایج مثبت نشان دهنده خطر بالای سکته قلبی می باشد. با وجود این، نتایج منفی دلیل بر قطعیت عدم وجود سکته قلبی و عدم انجام سایر آزمایشات مربوط به پیگیری سکته قلبی نمی باشد.
Sample type : whole blood, serum or plasma specimenscut-off of 1.0 ng/mLRelative sensitivity: 98.8% (95%CI*: 95.6%~99.8%)Relative specificity: 98.9% (95%CI*: 97.7%~99.5%)Accuracy: 98.8% (95%CI*: 97.8%~99.5%) *Confidence Intervals
The BIOSYNEX® Troponin Test is an immunochromatographic rapid test for the qualitativepresumptive detection of cardiac Troponin I in human whole blood, serum or plasmaspecimens. This kit is intended for use as an aid in the diagnosis of a myocardial infarction(MI). The test is designed for professional in vitro diagnostic use.A positive result indicates a high risk for myocardial infarction (MI). A negative result,however, does not exclude a MI and further follow-up testing is required including quantitativecardiac troponin testing.Cardiac Troponin I (cTnI) is a protein found in cardiac muscle with a molecular weight of 22.5kDa. Troponin I is part of a three subunit complex comprising of Troponin T and Troponin C.Along with tropomyosin, this structural complex forms the main component that regulates thecalcium sensitive ATPase activity of actomyosin in striated skeletal and cardiac muscle. Aftercardiac injury occurs, Troponin I is released into the blood 4-6 hours after the onset of pain.The release pattern of cTnI is similar to CK-MB, but while CK-MB levels return to normal after72 hours, Troponin I remains elevated for 6-10 days, thus providing for a longer window ofdetection for cardiac injury. The high specificity of cTnI measurements for the identification ofmyocardial damage has been demonstrated in conditions such as the perioperative period,after marathon runs, and blunt chest trauma. cTnI release has also been documented incardiac conditions other than acute myocardial infarction (AMI) such as unstable angina,congestive heart failure, and ischemic damage due to coronary artery bypass surgery.Because of its high specificity and sensitivity in the myocardial tissue, Troponin I has recentlybecome the most preferred biomarker for myocardial infarction